EUVIMEDEUVIMED entdecken
Crossref

Physiologically based Pharmacokinetic/Pharmacodynamic Modeling (PBPK/PD) of Famotidine in Pregnancy

Xiaomei I Liu, Dionna J Green, John van den Anker, Homa K Ahmadzia, Joaquin Calderon, Gilbert J Burckart iD, André Dallmann iD

The Journal of Clinical Pharmacology · 2025

DOI: 10.1002/jcph.6185 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Pharmacology, 2025. Verfasst von Xiaomei I Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Pharmacology, Children's National Hospital, Washington, DC, USA. Hauptthemen laut MEDLINE: Famotidine, Models, Biological, Histamine H2 Antagonists. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Famotidine, a H 2 ‐receptor antagonist, is commonly used to treat heartburn and gastroesophageal reflux disease during pregnancy. However, information on the pharmacokinetics (PK) of famotidine in pregnant patients is limited since pregnant patients are usually excluded from clinical trials. This study aimed to develop and evaluate a physiologically based pharmacokinetic (PBPK) model for famotidine in non‐pregnant and pregnant populations, and to combine it with a pharmacodynamic (PD) model to predict the effect of famotidine on intragastric pH. Clinical data for model evaluation were taken from the literature. The PBPK model successfully predicted famotidine PK in non‐pregnant and pregnant populations. The ratio of predicted versus observed PK parameters in non‐pregnant populations ranged from 0.66 to 1.33 for the area under the concentration–time curve and from 0.50 to 1.27 for peak concentration (C max ). In the pregnant populations, these ratios were 0.94 and 1.17 for early pregnancy, 0.82 and 1.29 for mid‐pregnancy, and 0.72 and 1.06 for late pregnancy, respectively. Compared to the non‐pregnant population, famotidine exposure was predicted to be decreased by, on average, 24% in mid‐pregnancy and 20% in late pregnancy. The PBPK/PD model adequately captured the increase in intragastric pH observed in non‐pregnant adults after famotidine intake and suggested a similar effect in mid‐ and late pregnancy. High inter‐individual variability and minor discrepancies between model predictions and clinical observations indicate a need for further clinical data to reliably inform dosing strategies and therapeutic outcomes for famotidine in pregnant populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FamotidineModels, BiologicalHistamine H2 AntagonistsHumansFemalePregnancyAdultYoung AdultHydrogen-Ion Concentration

Stichwörter der Autor:innen

famotidinepharmacodynamicsphysiologically based pharmacokineticspregnancy

Substanzen

FamotidineHistamine H2 Antagonists

Autor:innen und Institutionen

  • Division of Clinical Pharmacology, Children's National Hospital, Washington, DC, USA.
  • Office of Pediatric Therapeutics, US Food and Drug Administration, Silver Spring, MD, USA.
  • Division of OBGYN, George Washington Medical Center, Washington, DC, USA.
  • Office of Clinical Pharmacology, US Food and Drug Administration, Silver Spring, MD, USA.
  • Bayer HealthCare SAS, Lille, France, on behalf of:, Model-Informed Drug Development, Research and Development, Pharmaceuticals, Bayer AG, Leverkusen, Germany.

ORCID-Profile: Gilbert J Burckart, André Dallmann

Zitieren

APA

Liu, X. I., Green, D. J., van den Anker, J., Ahmadzia, H. K., Calderon, J., Burckart, G. J., & Dallmann, A. (2025). Physiologically based Pharmacokinetic/Pharmacodynamic Modeling (PBPK/PD) of Famotidine in Pregnancy. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.6185

Vancouver

Liu XI, Green DJ, van den Anker J, Ahmadzia HK, Calderon J, Burckart GJ, et al. Physiologically based Pharmacokinetic/Pharmacodynamic Modeling (PBPK/PD) of Famotidine in Pregnancy. The Journal of Clinical Pharmacology. 2025. doi:10.1002/jcph.6185

BibTeX
@article{Liu2025,
  author = {Liu, Xiaomei I and Green, Dionna J and van den Anker, John and Ahmadzia, Homa K and Calderon, Joaquin and Burckart, Gilbert J and Dallmann, André},
  title = {Physiologically based Pharmacokinetic/Pharmacodynamic Modeling (PBPK/PD) of Famotidine in Pregnancy},
  journal = {The Journal of Clinical Pharmacology},
  year = {2025},
  doi = {10.1002/jcph.6185}
}
Kostenlos starten →